Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07762755
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT07762755
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07762755. Randomized; single masking; primary purpose treatment. Start 2026-08-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
- Acronym
- IPE-NaF
- Condition
- Coronary Artery Disease
- Condition
- Hyperlipidaemia
- Condition
- Hypertriglyceridaemia
- Condition
- Coronary Atherosclerosis
- Intervention (Drug)
- icosapent ethyl (IPE)
- Intervention (Drug)
- Standard LDL-C-Lowering Therapy
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Collaborator
- Beijing Anzhen Hospital
- Collaborator
- Beijing Chao Yang Hospital
- Collaborator
- Beijing Municipal Health Commission
Record details
- Record id
cardio:ct-nct07762755- Content hash
bfaa247177e3489de8a9d1f7a00b877d11e60328c1046f8ee32e4537c3a6405d